From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea.
Despite its efficacy, the uptake of HU in adults with sickle cell disease (SCD) is poor likely due to a combination of system, provider, and patient-related factors. We investigated attitudes of adult patients towards HU by conducting qualitative interviews with 95 adult SCD patients (age 18 to 67 y...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2018-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC6021071?pdf=render |
| _version_ | 1819083044080844800 |
|---|---|
| author | Cynthia B Sinha Nitya Bakshi Diana Ross Lakshmanan Krishnamurti |
| author_facet | Cynthia B Sinha Nitya Bakshi Diana Ross Lakshmanan Krishnamurti |
| author_sort | Cynthia B Sinha |
| collection | DOAJ |
| description | Despite its efficacy, the uptake of HU in adults with sickle cell disease (SCD) is poor likely due to a combination of system, provider, and patient-related factors. We investigated attitudes of adult patients towards HU by conducting qualitative interviews with 95 adult SCD patients (age 18 to 67 years old, 71 were female). While 53% of all participants reported that they were currently taking HU, patients ranging in age 18-30 years (Group 1) were more likely to report current HU use as compared to those (Group 2) ranging in age 31-67 years (65% vs. 41% P = 0.01). Most Group 1 participants who reported currently taking HU indicated that the decision to start HU was made by a parent, though some made the decision themselves as a young adult. Group 1 participants expressed trust in the efficacy of HU as well as trust that their physician adequately shared risks and benefits for the medication. The Group 2 participants, who were not currently on HU, were skeptical that all the risks and benefits of HU were known, were concerned that the efficacy of HU was not proven, and that they were not receiving complete information about its potential side effects. Of Group 2 participants who reported currently being on HU, 25% were concerned about the side effects and efficacy of HU and reported continuing HU because of a lack of effective alternatives. These data suggest that there are significant differences by age in adult SCD patients' attitudes towards, utilization and understanding of the risks and benefits of HU. |
| first_indexed | 2024-12-21T20:26:18Z |
| format | Article |
| id | doaj.art-5befaba98d5c461780e5572ddf04617e |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-21T20:26:18Z |
| publishDate | 2018-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-5befaba98d5c461780e5572ddf04617e2022-12-21T18:51:21ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01136e019937510.1371/journal.pone.0199375From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea.Cynthia B SinhaNitya BakshiDiana RossLakshmanan KrishnamurtiDespite its efficacy, the uptake of HU in adults with sickle cell disease (SCD) is poor likely due to a combination of system, provider, and patient-related factors. We investigated attitudes of adult patients towards HU by conducting qualitative interviews with 95 adult SCD patients (age 18 to 67 years old, 71 were female). While 53% of all participants reported that they were currently taking HU, patients ranging in age 18-30 years (Group 1) were more likely to report current HU use as compared to those (Group 2) ranging in age 31-67 years (65% vs. 41% P = 0.01). Most Group 1 participants who reported currently taking HU indicated that the decision to start HU was made by a parent, though some made the decision themselves as a young adult. Group 1 participants expressed trust in the efficacy of HU as well as trust that their physician adequately shared risks and benefits for the medication. The Group 2 participants, who were not currently on HU, were skeptical that all the risks and benefits of HU were known, were concerned that the efficacy of HU was not proven, and that they were not receiving complete information about its potential side effects. Of Group 2 participants who reported currently being on HU, 25% were concerned about the side effects and efficacy of HU and reported continuing HU because of a lack of effective alternatives. These data suggest that there are significant differences by age in adult SCD patients' attitudes towards, utilization and understanding of the risks and benefits of HU.http://europepmc.org/articles/PMC6021071?pdf=render |
| spellingShingle | Cynthia B Sinha Nitya Bakshi Diana Ross Lakshmanan Krishnamurti From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea. PLoS ONE |
| title | From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea. |
| title_full | From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea. |
| title_fullStr | From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea. |
| title_full_unstemmed | From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea. |
| title_short | From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea. |
| title_sort | from trust to skepticism an in depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea |
| url | http://europepmc.org/articles/PMC6021071?pdf=render |
| work_keys_str_mv | AT cynthiabsinha fromtrusttoskepticismanindepthanalysisacrossagegroupsofadultswithsicklecelldiseaseontheirperspectivesregardinghydroxyurea AT nityabakshi fromtrusttoskepticismanindepthanalysisacrossagegroupsofadultswithsicklecelldiseaseontheirperspectivesregardinghydroxyurea AT dianaross fromtrusttoskepticismanindepthanalysisacrossagegroupsofadultswithsicklecelldiseaseontheirperspectivesregardinghydroxyurea AT lakshmanankrishnamurti fromtrusttoskepticismanindepthanalysisacrossagegroupsofadultswithsicklecelldiseaseontheirperspectivesregardinghydroxyurea |